Nektar Therapeutics to Participate in Two Investor Conferences in September
Nektar Therapeutics (NASDAQ:NKTR) announced its participation in two upcoming investor conferences in September 2025. The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10 at 10:30 AM ET in New York City, and the Stifel Virtual Immunology and Inflammation Forum on September 15 at 2:30 PM ET.
Both presentations will be available via webcast through the company's investor relations website, with replays accessible for 30 days. Investors interested in one-on-one meetings with management can arrange them through their representatives.
Nektar Therapeutics (NASDAQ:NKTR) ha annunciato la sua partecipazione a due conferenze per investitori previste per settembre 2025. La società presenterà al H.C. Wainwright 27th Annual Global Investment Conference il 10 settembre alle 10:30 ET a New York e al Stifel Virtual Immunology and Inflammation Forum il 15 settembre alle 14:30 ET.
Entrambe le presentazioni saranno trasmesse in webcast sul sito delle relazioni con gli investitori dell’azienda e le registrazioni resteranno disponibili per 30 giorni. Gli investitori interessati a incontri one-to-one con il management possono organizzarli tramite i propri rappresentanti.
Nektar Therapeutics (NASDAQ:NKTR) anunció su participación en dos conferencias para inversores en septiembre de 2025. La compañía presentará en el H.C. Wainwright 27th Annual Global Investment Conference el 10 de septiembre a las 10:30 ET en Nueva York, y en el Stifel Virtual Immunology and Inflammation Forum el 15 de septiembre a las 14:30 ET.
Ambas presentaciones estarán disponibles por webcast en la web de relaciones con inversores de la compañía, con repeticiones accesibles durante 30 días. Los inversores que deseen reuniones individuales con la dirección pueden solicitarlas a través de sus representantes.
Nektar Therapeutics (NASDAQ:NKTR)는 2025년 9월 개최되는 두 건의 투자자 컨퍼런스 참가를 발표했습니다. 회사는 9월 10일 오전 10시 30분(동부시간) 뉴욕에서 열리는 H.C. Wainwright 27th Annual Global Investment Conference와 9월 15일 오후 2시 30분(동부시간)에 개최되는 Stifel Virtual Immunology and Inflammation Forum에서 발표할 예정입니다.
두 발표 모두 회사 투자자 관계 웹사이트를 통해 웹캐스트로 제공되며, 재생 영상은 30일 동안 시청할 수 있습니다. 경영진과의 일대일 미팅을 원하시는 투자자는 담당자를 통해 신청하실 수 있습니다.
Nektar Therapeutics (NASDAQ:NKTR) a annoncé sa participation à deux conférences investisseurs prévues en septembre 2025. La société présentera lors du H.C. Wainwright 27th Annual Global Investment Conference le 10 septembre à 10h30 ET à New York, et au Stifel Virtual Immunology and Inflammation Forum le 15 septembre à 14h30 ET.
Les deux présentations seront diffusées en webcast sur le site relations investisseurs de la société, avec des replays accessibles pendant 30 jours. Les investisseurs souhaitant des rencontres individuelles avec la direction peuvent les organiser via leurs représentants.
Nektar Therapeutics (NASDAQ:NKTR) gab die Teilnahme an zwei bevorstehenden Investorenkonferenzen im September 2025 bekannt. Das Unternehmen wird am H.C. Wainwright 27th Annual Global Investment Conference am 10. September um 10:30 Uhr ET in New York sowie am Stifel Virtual Immunology and Inflammation Forum am 15. September um 14:30 Uhr ET präsentieren.
Beide Präsentationen werden als Webcast über die Investor-Relations-Website des Unternehmens verfügbar sein; Aufzeichnungen sind für 30 Tage abrufbar. Investoren, die Einzelgespräche mit dem Management wünschen, können diese über ihre Vertreter arrangieren.
- None.
- None.
- H.C. Wainwright 27th Annual Global Investment Conference on Wednesday, September 10, 2025 – webcast to be available at 10:30 a.m. Eastern Time / 7:30 a.m. Pacific Time – link here
- Stifel 2025 Virtual Immunology and Inflammation Forum on Monday, September 15, 2025 – webcast to be available at 2:30 p.m. Eastern Time / 11:30 a.m. Pacific Time – link here
The presentations will be accessible via the webcast links above as well as on the Investor Events section of the Nektar website: https://ir.nektar.com/events-and-presentations/events. Replays of the presentations will be available for 30 days.
If you would like to request a one-on-one meeting with company management during the conferences, please reach out to your respective representative.
About Nektar Therapeutics
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in two Phase 2b clinical trials, one in atopic dermatitis and one in alopecia areata. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar, together with various partners, is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. Nektar is headquartered in
Contact:
For Investors:
Vivian Wu of Nektar Therapeutics
628-895-0661
For Media:
Madelin Hawtin
LifeSci Communications
603-714-2638
mhawtin@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-two-investor-conferences-in-september-302545833.html
SOURCE Nektar Therapeutics
FAQ
When is Nektar Therapeutics (NKTR) presenting at the H.C. Wainwright Conference 2025?
When is NKTR's presentation at the Stifel Virtual Immunology Forum 2025?
How can investors access Nektar's (NKTR) September 2025 conference presentations?
How can investors schedule meetings with Nektar management at these conferences?
